Mesothelioma: The Treatment and Claims in 2025

Mesothelioma—a rare but aggressive cancer most often linked to asbestos exposure—remains challenging, but 2025 has ushered in meaningful progress on both treatment and legal fronts.

---

Cutting-Edge Treatment Developments

1. Immunotherapy Takes Center Stage

• The FDA approved Keytruda (pembrolizumab) combined with chemotherapy in September 2024 for inoperable pleural mesothelioma, offering modest survival gains Mesothelioma.com911meso.com.

• The previously approved combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to show improved outcomes, with median survival around 22 months—approximately 10 months better than traditional chemotherapy Mesothelioma.combraytonlaw.com911meso.com.

• The cancer vaccine UV1, administered alongside Opdivo and Yervoy, has received Fast Track status from the FDA. Early trials report a 27% reduction in death risk, potentially marking the first approved cancer vaccine for mesothelioma Mesothelioma.com911meso.com.

2. Targeted & Gene-Based Therapies

• Tazemetostat, an EZH2 inhibitor, shows promising results—especially among patients with BAP1 gene mutations, improving disease control with few side effects Mesothelioma.netasbestos.com.

• ADI-PEG20 (pegargiminase), which depletes arginine to starve tumor cells, demonstrated enhanced survival when combined with chemotherapy in the ATOMIC-Meso trial Mesothelioma.netMesotheliomaHope.com.

3. Gene & Molecular Therapy Innovations

• Pioneering efforts utilize CRISPR gene editing and viral gene therapy to target mesothelioma at its genetic core, disrupting key survival mechanisms braytonlaw.comkrwlawyers.com.

• IAG933, a small-molecule inhibitor targeting the YAP-TEAD interaction in the Hippo pathway, is now in Phase I trials for mesothelioma and similar solid tumors Wikipedia.

• Tulmimetostat, an oral dual inhibitor of EZH2/EZH1, is under investigation for BAP1-mutated mesothelioma and other cancers Wikipedia.

4. Diagnostics, Delivery, & Multimodal Approaches

• Combining immunotherapy with chemotherapy (e.g., durvalumab with cisplatin/pemetrexed) has elevated median survival from around 12 to 20.4 months in clinical trials Mesothelioma.net.

• Transarterial chemoperfusion, delivering chemotherapy directly to the tumor’s blood supply, has improved survival and quality of life Mesothelioma.net.

• Innovative diagnostics like inhalable gene therapy powders, liquid biopsies (e.g., CytoFind), and tumor-treating fields are advancing early detection and personalized treatment Mesothelioma.netWikipedia.

• ASCO’s updated 2025 guidelines now recommend genetic testing for all pleural mesothelioma patients and better define tumor subtypes (epithelioid, sarcomatoid, biphasic), refining treatment strategies MesotheliomaHope.com.

---

Legal Claims & Compensation Landscape

1. Major Verdicts & Ongoing Litigation

• A Massachusetts jury awarded $42.6 million to Paul Lovell in July 2025, finding Johnson & Johnson’s talc products caused his mesothelioma Reuters.

• This follows other large verdicts earlier in 2025, including $45 million in Illinois, $260 million in Oregon (later overturned), and $8–15 million in other cases Reuters.

2. Bankruptcy & Trust Fund Disputes

• Barretts Minerals, facing asbestos-related litigation, is challenged over its Chapter 11 filing; claimants argue the bankrupt entity has no operations and that its solvent parent should bear liability Wall Street Journal.

• Corporations like J&J, Dow, and Georgia-Pacific oppose the destruction of historical asbestos trust claims records, citing the need for transparency and fraud prevention Wall Street Journal.

3. Regulatory & Legislative Pressures

• States like Georgia, Missouri, and Arkansas have enacted laws restricting damages and shortening filing periods, potentially limiting mesothelioma compensation asbestos.com.

• In the UK, asbestos giant Altrad (formerly Cape) faces calls from MPs to donate more for research and risk being banned from government contracts unless it contributes £10 million The Times+1.

---

Summary

2025 brings renewed optimism for mesothelioma patients—not only through breakthroughs in immunotherapy, gene editing, targeted treatments, and diagnostics—but also through a shifting legal landscape marked by major verdicts and evolving regulatory challenges. Patients should explore all treatment avenues and seek experienced legal counsel to navigate both care and compensation.